TABLE 2.
Neuropsychiatric drug information study entry
| PD‐N | PD‐MCI | PDD | |
|---|---|---|---|
| Sedatives/Hypnotics | |||
| Zopiclone | 5 | 4 | 3 |
| Temazepam | 0 | 1 | 0 |
| Triazolam | 0 | 2 | 0 |
| Nitrazepam | 1 | 1 | 0 |
| Melatonin | 0 | 0 | 0 |
| Antipsychotics | |||
| Quetiapine | 4 | 4 | 10 |
| Clozapine | 1 | 0 | 1 |
| Olanzapine | 0 | 1 | 0 |
| Risperidone | 0 | 0 | 0 |
| Antidepressants | |||
| Selective serotonin reuptake inhibitors (SSRIs) | |||
| Citalopram | 10 | 13 | 10 |
| Escitalopram | 2 | 2 | 0 |
| Paroxetine | 1 | 1 | 0 |
| Fluoxetine | 9 | 3 | 1 |
| Cyclic and related agents | |||
| Nortriptyline | 1 | 6 | 0 |
| Amitriptyline | 6 | 6 | 2 |
| Dothiepin | 1 | 1 | 0 |
| Other antidepressants | |||
| Venlafaxine (SNRI) | 3 | 0 | 1 |
| Moclobemide (MAOI‐A) | 1 | 1 | 0 |
| Mirtazapine | 3 | 3 | 1 |
| Anxiolytics | |||
| Clonazepam | 7 | 3 | 3 |
| Diazepam | 0 | 0 | 0 |
| Lorazepam | 3 | 3 | 2 |
| Oxazepam | 0 | 0 | 0 |
| Anticholinesterase inhibitor | |||
| Donepezil | 0 | 2 | 5 |
| Rivastigmine | 1 | 1 | 2 |
Abbreviations: MAOI‐A, Monoamine oxidase inhibitors—Type A; PDD, Participants who met Level II criteria for Parkinson's disease with dementia; PD‐MCI, Participants who met Level II criteria for Parkinson's disease with mild cognitive impairment; PD‐N, The remaining Participants who did not meet criteria for PDD or PD‐MCI were classified as having normal cognition; SNRI, Serotonin‐noradrenaline reuptake inhibitors.